Strategic acquisitions Neopharm Labs has expanded through the acquisitions of Averica Discovery and MS Pharma, signaling potential for cross-sell of analytical development, discovery services, and contract research capabilities to new and existing clients in the pharmaceutical sector.

Canadian focus Aiming to be the reference in Canada for analytical services in life sciences suggests targeted opportunities with Canadian biotech and pharma companies seeking local expertise, regulatory alignment, and faster turnaround times.

Integrated partnerships Unified operation post acquisitions indicates streamlined project delivery and potential to upsell end-to-end services from discovery through commercialization, appealing to partners seeking single-vendor efficiency.

Growth and hiring Historical headcount additions and investments in new equipment imply capacity for scale and capability expansion, presenting opportunities to engage clients with larger or more complex analytical programs.

Technology stack Adoption of multiple enterprise tools (iCIMS, Salesforce, SAP, others) signals strong data and CRM capabilities that can be leveraged to tailor proactive outreach, account-based selling, and superior customer experience.